This initiative to tackle the threat of resistant pathogens is designed to make the use of international resources even more effective. It should enable research scientists to develop more new antibiotics and treatments against infections.
There has been a significant increase in antimicrobial resistance (AMR) in the last few decades making it a major threat to global health. The Global Antimicrobial Resistance Research and Development Hub – or Global AMR R&D Hub for short – is designed to tackle this trend. The Hub was launched on 22 May coinciding with the World Health Assembly in Geneva. It aims to further improve the coordination of international efforts and initiatives to tackle AMR while further increasing investments into R&D for AMR. In order to promote the development of more new drugs and treatments against resistant pathogens, resources need to be employed even more effectively than at present.
The German Federal Ministry of Education and Research will provide up to 500 million euros over the next ten years for AMR research
The German Federal Government has taken the lead in driving the establishment of the Global AMR R&D Hub: Under Germany´s presidency in 2017, the G20 heads of state and government took the decision to intensify global collaboration in the fight against AMR. The Federal Ministry of Education and Research (BMBF) then proposed plans for the Global AMR R&D Hub and supported its establishment. Initially, the secretariat of the Global AMR R&D Hub will be based in Berlin, at the German Center for Infection Research (DZIF). The BMBF will provide up to 500 million euros over the next ten years towards research to combat antimicrobial resistance.
New antibiotics are urgently needed to protect the health of people around the world and save lives. The inappropriate use of antibiotics has resulted in more and more bacterial strains developing resistance in the last few decades – with fatal consequences: According to World Health Organization estimates, approximately 25,000 people die each year from AMR infections in Europe alone.
Public funding is required to fight resistant pathogens
The research and development of new effective drugs against AMR, particularly of antibiotics, are highly challenging and provide little economic incentives for pharmaceutical companies. The result is that no groundbreaking new antibiotic has been brought onto the market in the last thirty years or so. And currently there is little sign of innovative breakthroughs in the pipeline. Public research funding therefore has a particular responsibility to help combat antimicrobial resistance. It must ensure that urgently needed research takes place, particularly in a field where only very limited returns on investments can be expected.
The members of the initiative – including countries like Russia, China, the United States and France, the European Commission, and funding organizations such as the Bill and Melinda Gates Foundation and the Wellcome Trust– confer on a regular basis. They identify important research and development tasks and jointly coordinate how to utilize their resources. The aim is to provide more effective funding for research and development of new treatments and diagnostics against resistant pathogens.
Interested countries and relevant non-governmental donor organizations can become members of the Global AMR R&D Hub. Other stakeholders are encouraged to participate by contributing their specific expertise. The Global AMR R&D Hub networks with other international initiatives in order to utilize synergies, including for example the European “Joint Programming Initiative on AMR” (JPIAMR) and the “Global Antibiotic Research & Development Partnership” (GARDP).
“One Health” approach against antimicrobial resistance
The work of the Global AMR R&D Hub will be aligned to the priorities set by the World Health Organization (WHO), the Food and Agriculture Organization of the United Nations (FAO) and the World Organisation for Animal Health (OIE). By including environmental aspects and veterinary medicine in its analyses and recommendations, the Global AMR R&D Hub lives up to the “One Health” approach whereby human and animal health, worldwide food safety and environmental factors are all considered as an interconnected whole.
[19.12.2018] Stakeholder Group: Call for Expression of Interest
Today the Global AMR R&D Hub launches its call for expressions of interest for organisations to join the AMR Hub Stakeholder Group. The Stakeholder Group is expected to support the work of the Global AMR R&D Hub to achieve the Hub’s objectives. Furthermore, it will facilitate consultation with stakeholders relevant for the work of the Global AMR R&D Hub.
The Board of the Global AMR R&D Hub has adopted a mandate for the Stakeholder Group. The document can be downloaded here: Mandate for the Stakeholder Group of the Global AMR R&D Hub
Seats on the SG are assigned based on pre-defined stakeholder categories and are equally distributed to ensure representation form each sub-group. The four pre-defined stakeholder groups are:
Each stakeholder sub-group will be represented by four or five members each.
Organisations that are interested to join the Stakeholder Group are invited to submit their application through the online-consultation.
Deadline for submission of expressions of interest is 31 January 2019 at 21:00 UTC.